The US FDA has approved acoltremon ophthalmic solution for the treatment of dry eye disease (DED). Acoltremon is a first-in-class transient receptor potential cation channel subfamily melastatin (M) member 8 (TRPM8) receptor agonist that activates corneal sensory nerves to promote a rapid increase in natural tear production. Clinical evidence In clinical trials involving 931 patients, significantly more patients treated with acoltremon achieved an increase in natural tear production exceeding 10 mm compared to those receiving the vehicle on day 14 (Study 1: 42.6% vs. 8.2%; Study 2: 53.2% vs.
14.4%). Notably, this effect persisted consistently through day 90. Dosage and administration Instill one drop in each eye twice daily (approximately 12 hours apart) Use a single-dose vial for both eyes immediately after opening, and discard it after use Acoltremon may be used concomitantly with…
